{"id":"NCT00604708","sponsor":"Valneva Austria GmbH","briefTitle":"Immunogenicity Study of the Japanese Encephalitis Vaccine IC51","officialTitle":"Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2006-09","completion":"2006-09","firstPosted":"2008-01-30","resultsPosted":"2012-11-29","lastUpdate":"2024-03-21"},"enrollment":867,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]},{"type":"BIOLOGICAL","name":"JE-VAX","otherNames":[]}],"arms":[{"label":"IC51","type":"EXPERIMENTAL"},{"label":"JE-VAX","type":"ACTIVE_COMPARATOR"}],"summary":"The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged \\> or = 18 years","primaryOutcome":{"measure":"SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56","timeFrame":"Day 56","effectByArm":[{"arm":"IC51","deltaMin":96.4,"sd":null},{"arm":"JE-VAX","deltaMin":93.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":428},"commonTop":["Headache","Myalgia","Influenza like Ilness","Fatigue","Nausea"]}}